Company: SUPN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0001356576-25-000017
Chunk: 646

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1
Chunk 646
---
 other disruptions could compromise our information and expose us to liability which would cause our business and reputation to suffer.53•Compliance with the terms and conditions of our Corporate Integrity Agreement requires significant resources and management time and, if we fail to comply, we could be subject to penalties or, under certain circumstances, excluded from government healthcare programs, which would materially adversely affect our business.56Risks Related to Our Finances and Capital Requirements•Our operating results may fluctuate significantly.56•Our ability to use our net operating loss carryforwards and other tax attributes may be limited or may expire prior to utilization.57•We have and may further expand our business through acquisitions of new product lines or businesses, which expose us to various risks, including difficulties in integrating acquisitions. Our recent acquisitions pose certain incremental risks to the Company. 58•Any impairment in the value of our intangible assets, including goodwill, would negatively affect our operating results and total capitalization.60Risks Related to Securities Markets and Investment in Our Stock•The issuance of additional shares of our common stock, or instruments convertible into or rights to acquire shares or our common stock, or market sales of our common stock, could affect the market price of our common stock.61•Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could negatively impact the market price of our common stock.62General Risk Factors•Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies. Our patent protection could be reduced or eliminated for non-compliance with these requirements.64•Our insurance coverage may not be sufficient to cover our legal claims or other losses that we may incur in the future.64•Our operations rely on sophisticated information technology, systems, and infrastructure, a disruption of which could harm our operations.65

Risks Related to Our Industry and Business

We are dependent on the commercial success of our products in the U.S.

Our financial performance, including our ability to replace revenue and income lost to generic products and other competitors as well as to grow our business, depends heavily on the commercial success of our products. A substantial amount of our resources is focused on generating, maintaining and/or expanding the revenue generated by our approved products in the U.S. Our major products Qelbree®, GOCOVRI®, Oxtellar XR®, and APOKYN®, represented approximately 38%, 20%, 16%, and 12% of